Promimic AB is a Sweden-based biomaterial company. The Company manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The Company operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
23/26/23	SEK 9.000	-5.76%	2,387
21/26/21	SEK 9.550	0.00%	1,000
20/26/20	SEK 9.550	-3.54%	101
19/26/19	SEK 9.900	+3.66%	500
16/26/16	SEK 9.550	-2.05%	225

Delayed Quote Nasdaq Stockholm

More quotes

Market Closed - Nasdaq Stockholm 09:30:00 23/10/2026 pm IST			5-day change	1st Jan Change
9.000 ^SEK	-5.76%		-7.69%	-46.90%

20/08	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
19/05	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE

Market Cap	17Cr 1.71Cr 1.53Cr 1.41Cr 1.28Cr 2.4Cr 162.66Cr 2.44Cr 6.73Cr 85Cr 6.43Cr 6.29Cr 270.71Cr	P/E 2024	-33.7x	P/E 2025	-36.6x
Enterprise Value	15Cr 1.51Cr 1.34Cr 1.24Cr 1.13Cr 2.11Cr 142.92Cr 2.14Cr 5.91Cr 75Cr 5.65Cr 5.53Cr 237.86Cr	EV / Sales 2024	7.85x	EV / Sales 2025	6.74x
Free-Float	23.31%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	PRO	Delayed
Deutsche Boerse AG	B0T	Delayed
Börse Stuttgart	B0T	Delayed
Boerse Muenchen	B0T	Real-time

20/08	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
19/05	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE
19/05	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Promimic nomination committee proposes new chairman	RE
24/02	Promimic Q4 net sales SEK 11.5 mln	RE
24/02	Promimic AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
19/11	Promimic Q3 sales of SEK 12.9 mln	RE
19/11	Promimic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/25/22	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/25/11	Promimic's CFO Heidi Bader makes a minor share purchase	FW
15/25/15	Promimic reports slightly lower operating loss	FW
15/25/15	Promimic Q1 Sales Increase 1.4% To 8.8 Msek	RE
15/25/15	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Promimic AB Share Price

Stocks

PRO

SE0017487242

Biotechnology & Medical Research

Valuation: Promimic AB

Chart: Promimic AB

Latest news: Promimic AB

Analysts' recommendations: Promimic AB

Press Releases: Promimic AB

Quotes and Performance

Price Extremes

Managers and Directors: Promimic AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-5.76%
1 week	-7.69%
Current month	-11.76%
1 month	-7.22%
3 months	-10.00%
6 months	-15.09%
Current year	-46.90%

1 week	9	9.9
1 month	9	10.3
Current year	7.7	16.55
1 year	7.7	19.45
3 years	7.7	45
5 years	7.7	45
10 years	7.7	45

Manager	Title	Age	Since
Per Gunnar Kjellin CTO	Chief Tech/Sci/R&D Officer	54	01/01/2004
Magnus Larsson CEO	Chief Executive Officer	63	18/01/2017
Heidi Bader DFI	Director of Finance/CFO	45	01/01/2023

Director	Title	Age	Since
Helena Maria Brisby BRD	Director/Board Member	61	01/01/2021
Johan Dighed BRD	Director/Board Member	53	01/01/2021
Pehr Abrahamsson CHM	Chairman	59	21/05/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/10/24	Magnus Larsson	Exercice	Chief Executive Officer	16,000	0.0869%
11/10/24	Magnus Larsson	Exercice	Chief Executive Officer	1,60,000	0.8685%
11/10/24	Magnus Larsson	Sell	Chief Executive Officer	1,25,000	0.6785%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROMIMIC AB	-5.76%	-7.69%	-34.78%	-66.79%	1.82Cr
WUXI APPTEC CO., LTD.	+2.41%	-6.33%	+43.43%	+71.02%	6.33TCr
ARGENX SE	-0.15%	+3.11%	+10.29%	+72.56%	5.49TCr
LONZA GROUP AG	+0.57%	+4.64%	+12.82%	+89.79%	5.33TCr
IQVIA HOLDINGS INC.	+0.37%	+3.07%	+28.23%	+51.53%	4.58TCr
BEONE MEDICINES AG	-1.21%	+0.95%	+20.44%	+128.58%	4.35TCr
REVOLUTION MEDICINES, INC.	-0.37%	-1.20%	+252.94%	+568.54%	4.02TCr
CELLTRION, INC.	+0.05%	+6.75%	+14.48%	+56.75%	3.35TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-5.84%	+27.86%	-0.65%	2.37TCr
GENMAB A/S	-0.38%	+4.55%	+37.71%	+28.10%	2.38TCr
Average	-0.33%	+0.09%	+41.34%	+99.94%	3.82TCr
Weighted average by Cap.	+0.38%	+0.55%	+48.17%	+122.11%

	2024	2025
Net sales	4.89Cr 49.29L 43.97L 40.63L 36.84L 69.02L 47Cr 70.05L 1.93Cr 24Cr 1.85Cr 1.81Cr 78Cr	4.44Cr 44.76L 39.94L 36.91L 33.46L 62.69L 42Cr 63.63L 1.76Cr 22Cr 1.68Cr 1.64Cr 71Cr
Net income	-1.26Cr -12.65L -11.28L -10.43L -9L -17.71L -12Cr -17.98L -49.64L -6.28Cr -47.45L -46.45L -20Cr	-87.54L -9L -8L -7L -7L -12.35L -8.37Cr -12.54L -34.63L -4.38Cr -33.1L -32.4L -14Cr
Net Debt	-3.58Cr -36.04L -32.16L -29.71L -26.94L -50.47L -34Cr -51.23L -1.41Cr -18Cr -1.35Cr -1.32Cr -57Cr	-2.06Cr -20.79L -18.55L -17.14L -15.54L -29.11L -20Cr -29.55L -81.6L -10Cr -78L -76.35L -33Cr